Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 10/20 | 0.44 |
| ▸ | CTSK | P43235 | 9/20 | 0.44 |
| ▸ | CTSB | P07858 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.44 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744721 | 1.00 | KLK5 (0.50) | KLK5CTSSCTSKCTSBSMN1; SMN2 | |
| SCHEMBL1743843 | 0.90 | ACE (0.55) | CTSSCTSKCTSBALDH1A1MAPT | |
| SCHEMBL20415708 | 0.88 | TAS1R3 (0.52) | KLK5CTSSCTSKCTSBNPC1 | |
| SCHEMBL18262693 | 0.88 | TAS1R3 (0.52) | KLK5CTSSCTSKCTSBNPC1 | |
| SCHEMBL24503057 | 0.86 | KLK5 (0.46) | KLK5CTSSCTSKCTSBACE | |
| SCHEMBL20397635 | 0.86 | KLK5 (0.46) | KLK5CTSSCTSKCTSBACE | |
| SCHEMBL8248143 | 0.84 | CYP3A4 (0.48) | SMN1; SMN2KDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL16460098 | 0.84 | SMN1; SMN2 (0.46) | CTSSCTSKCTSBSMN1; SMN2KDM4E | |
| SCHEMBL16460097 | 0.84 | SMN1; SMN2 (0.46) | CTSSCTSKCTSBSMN1; SMN2KDM4E | |
| SCHEMBL1744778 | 0.83 | ATM (0.45) | SMN1; SMN2NPC1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | KLK5 1677/4885CTSS 2788/4885CTSK 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.